Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016)

References

• Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. Nature. 2000;408:239–247.
   PubMed Web of Science ®Google Scholar
• Boutten A, Goven D, Artaud-Macari E, et al. NRF2 targeting: a promising therapeutic strategy in chronic obstructive pulmonary disease. Trends Mol Med. 2011;17:363–371.
   PubMed Web of Science ®Google Scholar
• Cho HY, Kwak MK, Pi J. Nrf2 in host defense: over the rainbow. Oxid Med Cell Longev. 2013;2013:975839.
   PubMed Web of Science ®Google Scholar
• Bauer AK, Hill T 3rd, Alexander CM. The involvement of NRF2 in lung cancer. Oxid Med Cell Longev. 2013;2013:746432.
   PubMed Web of Science ®Google Scholar
• Hong WK, Sporn MB. Recent advances in chemoprevention of cancer. Science. 1997;278:1073–1077.
   PubMed Web of Science ®Google Scholar
• Baird L, Dinkova-Kostova AT. The cytoprotective role of the Keap1-Nrf2 pathway. Arch Toxicol. 2011;85:241–272.
   PubMed Web of Science ®Google Scholar
• Sporn MB. Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res. 1976;36:2699–2702.
   PubMed Web of Science ®Google Scholar
• Kelloff GJ, Lieberman R, Steele VE, et al. Agents, biomarkers, and cohorts for chemopreventive agent development in prostate cancer. Urology. 2001;57:46–51.
   PubMed Web of Science ®Google Scholar
• Kakizoe T. Chemoprevention of cancer–focusing on clinical trials. Jpn J Clin Oncol. 2003;33:421–442.
   PubMed Web of Science ®Google Scholar
• Kwak MK, Egner PA, Dolan PM, et al. Role of phase 2 enzyme induction in chemoprotection by dithiolethiones. Mutat Res. 2001;480–481:305–315.
   PubMed Web of Science ®Google Scholar
• Stepkowski TM, Kruszewski MK. Molecular cross-talk between the NRF2/KEAP1 signaling pathway, autophagy, and apoptosis. Free Radic Biol Med. 2011;50:1186–1195.
   PubMed Web of Science ®Google Scholar
• Malhotra D, Portales-Casamar E, Singh A, et al. Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChIP-Seq profiling and network analysis. Nucleic Acids Res. 2010;38:5718–5734.
   PubMed Web of Science ®Google Scholar
• Rushmore TH, Morton MR, Pickett CB. The antioxidant responsive element. Activation by oxidative stress and identification of the DNA consensus sequence required for functional activity. J Biol Chem. 1991;266:11632–11639.
   PubMed Web of Science ®Google Scholar
• Friling RS, Bensimon A, Tichauer Y, et al. Xenobiotic-inducible expression of murine glutathione S-transferase Ya subunit gene is controlled by an electrophile-responsive element. Proc Natl Acad Sci. 1990;87:6258–6262.
   PubMed Web of Science ®Google Scholar
• Itoh K, Chiba T, Takahashi S, et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun. 1997;236:313–322.
   PubMed Web of Science ®Google Scholar
• Yu X, Kensler T. Nrf2 as a target for cancer chemoprevention. Mutat Res. 2005;591:93–102.
   PubMed Web of Science ®Google Scholar
• De Vries HE, Witte M, Hondius D, et al. Nrf2-induced antioxidant protection: a promising target to counteract ROS-mediated damage in neurodegenerative disease? Free Radic Biol Med. 2008;45:1375–1383.
   PubMed Web of Science ®Google Scholar
• Marzec JM, Christie JD, Reddy SP, et al. Functional polymorphisms in the transcription factor NRF2 in humans increase the risk of acute lung injury. Faseb J. 2007;21:2237–2246.
   PubMed Web of Science ®Google Scholar
• Theiss AL, Vijay-Kumar M, Obertone TS, et al. Prohibitin is a novel regulator of antioxidant response that attenuates colonic inflammation in mice. Gastroenterology. 2009;137:199–208.
   PubMed Web of Science ®Google Scholar
• Nagai N, Thimmulappa RK, Cano M, et al. Nrf2 is a critical modulator of the innate immune response in a model of uveitis. Free Radic Biol Med. 2009;47:300–306.
   PubMed Web of Science ®Google Scholar
• Abed DA, Goldstein M, Albanyan H, et al. Discovery of direct inhibitors of Keap1-Nrf2 protein-protein interaction as potential therapeutic and preventive agents. Acta Pharm Sin B. 2015;5:285–299.
   PubMed Web of Science ®Google Scholar
• Zhuang C, Miao Z, Sheng C, et al. Updated research and applications of small molecule inhibitors of Keap1-Nrf2 protein-protein interaction: a review. Curr Med Chem. 2014;21:1861–1870.
   PubMed Web of Science ®Google Scholar
• O’Connell MA, Hayes JD. The Keap1/Nrf2 pathway in health and disease: from the bench to the clinic. Biochem Soc Trans. 2015;43:687–689.
   PubMed Web of Science ®Google Scholar
• Reuter S, Gupta SC, Chaturvedi MM, et al. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med. 2010;49:1603–1616.
   PubMed Web of Science ®Google Scholar
• Lu MC, Ji JA, Jiang ZY, et al. The Keap1–Nrf2–ARE pathway as a potential preventive and therapeutic target: an update. Med Res Rev. 2016;36:924–963.
   PubMed Web of Science ®Google Scholar
• Moi P, Chan K, Asunis I, et al. Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proc Natl Acad Sci USA. 1994;91:9926–9930.
   PubMed Web of Science ®Google Scholar
• Motohashi H, Yamamoto M. Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends Mol Med. 2004;10:549–557.
   PubMed Web of Science ®Google Scholar
• Katoh Y, Iida K, Kang MI, et al. Evolutionary conserved N-terminal domain of Nrf2 is essential for the Keap1-mediated degradation of the protein by proteasome. Arch Biochem Biophys. 2005;433:342–350.
   PubMed Web of Science ®Google Scholar
• Wakabayashi N, Dinkova-Kostova AT, Holtzclaw WD, et al. Protection against electrophile and oxidant stress by induction of the phase 2 response: fate of cysteines of the Keap1 sensor modified by inducers. Proc Natl Acad Sci USA. 2004;101:2040–2045.
   PubMed Web of Science ®Google Scholar
• Wakabayashi N, Itoh K, Wakabayashi J, et al. Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation. Nat Genet. 2003;35:238–245.
   PubMed Web of Science ®Google Scholar
• Dinkova-Kostova AT, Holtzclaw WD, Cole RN, et al. Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc Natl Acad Sci USA. 2002;99:11908–11913.
   PubMed Web of Science ®Google Scholar
• Zhang DD, Lo SC, Cross JV, et al. Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol Cell Biol. 2004;24:10941–10953.
   PubMed Web of Science ®Google Scholar
• Furukawa M, Xiong Y. BTB protein Keap1 targets antioxidant transcription factor Nrf2 for ubiquitination by the Cullin 3-Roc1 ligase. Mol Cell Biol. 2005;25:162–171.
   PubMed Web of Science ®Google Scholar
• Cullinan SB, Gordan JD, Jin J, et al. The Keap1-BTB protein is an adaptor that bridges Nrf2 to a Cul3-based E3 ligase: oxidative stress sensing by a Cul3-Keap1 ligase. Mol Cell Biol. 2004;24:8477–8486.
   PubMed Web of Science ®Google Scholar
• McMahon M, Thomas N, Itoh K, et al. Redox-regulated turnover of Nrf2 is determined by at least two separate protein domains, the redox-sensitive Neh2 degron and the redox-insensitive Neh6 degron. J Biol Chem. 2004;279:31556–31567.
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Itoh K, Suzuki T, et al. Identification of the interactive interface and phylogenic conservation of the Nrf2-Keap1 system. Genes Cells. 2002;7:807–820.
   PubMed Web of Science ®Google Scholar
• Tong KI, Kobayashi A, Katsuoka F, et al. Two-site substrate recognition model for the Keap1-Nrf2 system: a hinge and latch mechanism. Biol Chem. 2006;387:1311–1320.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Yamamoto M. Molecular basis of the Keap1-Nrf2 system. Free Radic Biol Med. 2015;88:93–100.
   PubMed Web of Science ®Google Scholar
• Dhakshinamoorthy S, Long DJ, Jaiswal AK. Antioxidant regulation of genes encoding enzymes that detoxify xenobiotics and carcinogens. Curr Top Cell Regul. 2000;36:201–216.
   PubMedGoogle Scholar
• Guo Y, Yu S, Zhang C, et al. Epigenetic regulation of Keap1-Nrf2 signaling. Free Radic Biol Med. 2015;88:337–349.
   PubMed Web of Science ®Google Scholar
• Na HK, Surh YJ. Oncogenic potential of Nrf2 and its principal target protein heme oxygenase-1. Free Radic Biol Med. 2014;67C:353–365.
   Web of Science ®Google Scholar
• Jiang ZY, Lu MC, You QD. Discovery and development of Kelch-like ECH-associated protein 1. Nuclear factor erythroid 2-related factor 2 (KEAP1: NRF2)protein-protein interaction inhibitors: achievements, challenges, and future directions. J Med Chem. 2016;59:10837–10858.
   PubMed Web of Science ®Google Scholar
• Richardson BG, Jain AD, Speltz TE, et al. Non-electrophilic modulators of the canonical Keap1/Nrf2 pathway. Bioorg Med Chem Lett. 2015;25:2261–2268.
   PubMed Web of Science ®Google Scholar
• Wells G. Peptide and small molecule inhibitors of the Keap1-Nrf2 protein-protein interaction. Biochem Soc Trans. 2015;43:674–679.
   PubMed Web of Science ®Google Scholar
• Wang XJ, Sun Z, Villeneuve NF, et al. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis. 2008;29:1235–1243.
   PubMed Web of Science ®Google Scholar
• Marchan R, Bolt HM. The cytoprotective and the dark side of Nrf2. Arch Toxicol. 2013;87:2047–2050.
   PubMed Web of Science ®Google Scholar
• Deeks ED. Dimethyl fumarate: a review in relapsing-remitting MS. Drugs. 2016;76:243–254.
   PubMed Web of Science ®Google Scholar
• Jing X, Shi H, Zhang C, et al. Dimethyl fumarate attenuates 6-OHDA-induced neurotoxicity in SH-SY5Y cells and in animal model of Parkinson’s disease by enhancing Nrf2 activity. Neuroscience. 2015;286:131–140.
   PubMed Web of Science ®Google Scholar
• Schulze-Topphoff U, Varrin-Doyer M, Pekarek K, et al. Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2. Proc Natl Acad Sci USA. 2016;113:4777–4782.
   PubMed Web of Science ®Google Scholar
• Morroni F, Tarozzi A, Sita G, et al. Neuroprotective effect of sulforaphane in 6-hydroxydopamine-lesioned mouse model of Parkinson’s disease. Neurotoxicology. 2013;36:63–71.
   PubMed Web of Science ®Google Scholar
• Patel V, Zhang X, Tautiva NA, et al. Small molecules and Alzheimer’s disease: misfolding, metabolism and imaging. Curr Alzheimer Res. 2015;12:445–461.
   PubMed Web of Science ®Google Scholar
• Chen X, inventor Zhenjiang Shengan Pharmaceutical Co., Ltd., Peop. Rep. China. assignee. Derivatives of dimethyl fumarate and application in the treatment of multiple sclerosis. CN103724198A. 2014.
   Google Scholar
• Li D, inventor Chengdu Sourcebio Limited Liability Company, Peop. Rep. China. assignee. Application of deuterated fumaric acid derivatives for treating multiple sclerosis. CN104415026A. 2015.
   Google Scholar
• Liby KT, Sporn MB. Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease. Pharmacol Rev. 2012;64:972–1003.
   PubMed Web of Science ®Google Scholar
• De Zeeuw D, Akizawa T, Audhya P, et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med. 2013;369:2492–2503.
   PubMed Web of Science ®Google Scholar
• Cleasby A, Yon J, Day PJ, et al. Structure of the BTB domain of keap1 and its interaction with the triterpenoid antagonist CDDO. PloS One. 2014;9:e98896.
   PubMed Web of Science ®Google Scholar
• Pergola PE, Raskin P, Toto RD, et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med. 2011;365:327–336.
   PubMed Web of Science ®Google Scholar
• Anderson E, Jiang X, Visnick M, et al., inventors; Reata Pharmaceuticals, INC., assignee. C4-monomethyl triterpenoid derivatives and methods of use thereof. WO2012125488A1. 2012.
   Google Scholar
• Anderson E, Decker A, Liu X, inventors; Reata Pharmaceuticals, INC., assignee. 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof. WO2013163344A1. 2012.
   Google Scholar
• Jiang X, Bender CF, Visnick M, inventors; Reata Pharmaceuticals, Inc., USA. assignee. Preparation of C13-hydroxy derivatives of oleanolic acid and methods of use thereof as antioxidant inflammation modulators. WO2014040073A1. 2014.
   Google Scholar
• Komoriya S, Nakagami Y, Hatano E, et al., inventors; Daiichi Sankyo company, Ltd., JP, assignee. Terpenoid derivative. WO2014148455A1. 2014.
   Google Scholar
• Nakagami Y, Masuda K, Hatano E, et al. Novel Nrf2 activators from microbial transformation products inhibit blood-retinal barrier permeability in rabbits. Br J Pharmacol. 2015;172:1237–1249.
   PubMed Web of Science ®Google Scholar
• Gribble GW, Sporn MB, Liby KT, et al. inventors; Trustees of Dartmouth College, USA. assignee. Preparation of pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)dien-28-oyl)imidazole. WO2016033132A1. 2016.
   Google Scholar
• Chin MP-H, Meyer CJ, inventors; REATA Pharmaceuticals, Inc., USA. assignee. Methods of treating and preventing endothelial dysfunction using bardoxololone methyl or analogs thereof. WO2015027206A1. 2015.
   Google Scholar
• Mohan C, Wu T, Andreeff M, inventors; University of Houston System, USA. assignee. CDDO-Me as a therapy for lupus and other autoimmune diseases. WO2016081701A2. 2016.
   Google Scholar
• Attucks OC, inventor VTV Therapeutics LLC, USA. assignee. Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof. WO2016089648A1. 2016.
   Google Scholar
• Biswal S, Thimmulappa R, Kumar S, et al., inventors; The Johns Hopkins University, USA. assignee. Chalcone derivatives as Nrf2 activators, their preparation and therapeutic use. WO2012116362A2. 2012.
   Google Scholar
• Childers WE, Abou-Gharbia M, Biswal S, et al., inventors; Cureveda, LLC, USA. assignee. Functionalized heteroaryl enones exhibiting Nrf2 activation and their method of use. WO2015187934A1. 2015.
   Google Scholar
• Lounsbury N, Mateo G, Jones B, et al. Heterocyclic chalcone activators of nuclear factor (erythroid-derived 2)-like 2 (Nrf2) with improved in vivo efficacy. Bioorg Med Chem. 2015;23:5352–5359.
   PubMed Web of Science ®Google Scholar
• Kim DJ, Park KD, Park WS, et al. inventors; Korea Institute of Science and Technology, S. Korea. assignee. Preparation of aromatic compounds containing activated vinyl group for treatment of neurological disorders through nitric oxide generation inhibition and Nrf2 activation. WO2013165140A1. 2013.
   Google Scholar
• Kachadourian R, Day BJ, Pugazhenti S, et al. A synthetic chalcone as a potent inducer of glutathione biosynthesis. J Med Chem. 2012;55:1382–1388.
   PubMed Web of Science ®Google Scholar
• Peng S, Zhang B, Meng X, et al. Synthesis of piperlongumine analogues and discovery of nuclear factor erythroid 2-related factor 2 (Nrf2) activators as potential neuroprotective agents. J Med Chem. 2015;58:5242–5255.
   PubMed Web of Science ®Google Scholar
• Xi MY, Sun ZY, Sun HP, et al. Synthesis and bioevaluation of a series of alpha-pyrone derivatives as potent activators of Nrf2/ARE pathway (part I). Eur J Med Chem. 2013;66:364–371.
   PubMed Web of Science ®Google Scholar
• Xi MY, Jia JM, Sun HP, et al. 3-aroylmethylene-2,3,6,7-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4(11bH)-ones as potent Nrf2/ARE inducers in human cancer cells and AOM-DSS treated mice. J Med Chem. 2013;56:7925–7938.
   PubMed Web of Science ®Google Scholar
• You Q, Yang T, Sun H, et al., inventors; China Pharmaceutical University, Peop. Rep. China. assignee. Pyridopyrazine compounds as Nrf2 activators and their preparation, pharmaceutical compositions and use in the treatment of inflammation and cancer. CN105566323A. 2016.
   Google Scholar
• Leon Martinez R, Buendia Abaitua I, Gonzalez de Mesa EN, et al., inventors; Fundacion para la investigacion Biomedica del Hospital Universitario de la Princesa, Spain; Universidad Autonoma de Madrid; DNS NeuroScience. assignee. Compounds derived from 3-alkylamino-1H-indole acrylate, and the use thereof in the treatment of neurodegenerative diseases. WO2016059269A1. 2016.
   Google Scholar
• Umesawa K, Hakamada M, Goto Y, inventors; Keio University, Japan. assignee. Nrf2 activators containing 2-hydroxybenzamide derivative, method for activating Nrf2, and pharmaceuticals containing the compound. JP2012082173A. 2012.
   Google Scholar
• Niitsu Y, Hakamata M, Goto Y, et al. Chemoenzymatic synthesis of (2R,3R,4R)-dehydroxymethylepoxyquinomicin (DHMEQ), a new activator of antioxidant transcription factor Nrf2. Org Biomol Chem. 2011;9:4635–4641.
   PubMed Web of Science ®Google Scholar
• Chen J, Li P, Zhang L, et al., inventors; China Pharmaceutical University, Peop. Rep. China. assignee. Application of 15,16-dihydrotanshinone I in manufacture of medicament for protection of vascular endothelium. CN105267225A. 2016
   Google Scholar
• Chen W, Xu Y, Liu B, inventors; Guangdong Hospital of Traditional Chinese Medicine, Peop. Rep. China. assignee. Antioxidant application of artemisitene in composition with treatment or health-care effect. CN104825443A. 2015.
   Google Scholar
• Le Lamer AC, Authier H, Rouaud I, et al. Protolichesterinic acid derivatives: alpha-methylene-gamma-lactones as potent dual activators of PPARgamma and Nrf2 transcriptional factors. Bioorg Med Chem Lett. 2014;24:3819–3822.
   PubMed Web of Science ®Google Scholar
• Fischedick JT, Standiford M, Johnson DA, et al. Structure activity relationship of phenolic diterpenes from Salvia officinalis as activators of the nuclear factor E2-related factor 2 pathway. Bioorg Med Chem. 2013;21:2618–2622.
   PubMed Web of Science ®Google Scholar
• Vrba J, Gazak R, Kuzma M, et al. A novel semisynthetic flavonoid 7-O-galloyltaxifolin upregulates heme oxygenase-1 in RAW264.7 cells via MAPK/Nrf2 pathway. J Med Chem. 2013;56:856–866.
   PubMed Web of Science ®Google Scholar
• Chao J, Lucas B, inventors; Biogen MA Inc., USA. assignee. Preparation of diterpenoid derivatives and methods of use thereof as medicinals. WO2016065264A1. 2016
   Google Scholar
• Wang B, Zhao Y, Sun K, inventors; Zhejiang Ocean University, Peop. Rep. China. assignee. Sphyrna flesh antioxidant peptide capable of activating nrf2-are pathway. CN105622720A. 2016.
   Google Scholar
• Hseu Y-C, Yang H-L, inventors; China Medical University, Taiwan. assignee. Use of ergothioneine for inducing activity of nuclear factor erythroid 2-related factor-2 (Nrf2) in cell. EP2992882A1. 2016.
   Google Scholar
• Ishii Y, Yageta Y, inventors; Tsukuba University, Japan; Kyorin Pharmaceutical Co., Ltd. assignee. Anti-oxidative stress enzyme expression inducers and promoters, Nrf2 activators, and Nrf2 nuclear import promoters. JP2013043851A. 2013
   Google Scholar
• Lo SC, Li X, Henzl MT, et al. Structure of the Keap1: Nrf2interface provides mechanistic insight into Nrf2 signaling. EMBO J. 2006;25:3605–3617.
   PubMed Web of Science ®Google Scholar
• Padmanabhan B, Tong KI, Ohta T, et al. Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. Molecular Cell. 2006;21:689–700.
   PubMed Web of Science ®Google Scholar
• Marcotte D, Zeng W, Hus JC, et al. Small molecules inhibit the interaction of Nrf2 and the Keap1 Kelch domain through a non-covalent mechanism. Bioorg Med Chem. 2013;21:4011–4019.
   PubMed Web of Science ®Google Scholar
• Jiang ZY, Lu MC, Xu LL, et al. Discovery of potent Keap1-Nrf2 protein-protein interaction inhibitor based on molecular binding determinants analysis. J Med Chem. 2014;57:2736–2745.
   PubMed Web of Science ®Google Scholar
• Jain AD, Potteti H, Richardson BG, et al. Probing the structural requirements of non-electrophilic naphthalene-based Nrf2 activators. Eur J Med Chem. 2015;103:252–268.
   PubMed Web of Science ®Google Scholar
• Jiang ZY, Xu LL, Lu MC, et al. Structure-activity and structure-property relationship and exploratory in vivo evaluation of the nanomolar Keap1-Nrf2 protein-protein interaction inhibitor. J Med Chem. 2015;58:6410–6421.
   PubMed Web of Science ®Google Scholar
• You Q, Jiang Z, Lu M, et al., inventors; China Pharmaceutical University, Peop. Rep. China. assignee. 1-Sulfonamido-4-aryloxynaphthalene compounds as Nrf2 activators and their preparation, pharmaceutical compositions and use in the treatment of diseases. CN105566241A. 2016.
   Google Scholar
• Hu L, Inoyama D, inventors; The State University of New Jersey, USA; Rutgers, The State University of New Jersey. assignee. High-throughput screening fluorescence polarization assay for inhibitors of Keap1-Nrf2 interaction. US20120202298A1. 2012.
   Google Scholar
• Hu L, Magesh S, Chen L, et al., inventors; The State University of New Jersey, USA; The Broad Institute, Inc. assignee. Direct inhibitors of Keap1-Nrf2 interaction as antioxidant inflammation modulators. WO2013067036A1. 2013.
   Google Scholar
• Hu L, Magesh S, Chen L, et al. Discovery of a small-molecule inhibitor and cellular probe of Keap1-Nrf2 protein-protein interaction. Bioorg Med Chem Lett. 2013;23:3039–3043.
   PubMed Web of Science ®Google Scholar
• Jnoff E, Albrecht C, Barker JJ, et al. Binding mode and structure-activity relationships around direct inhibitors of the Nrf2-Keap1 complex. ChemMedChem. 2014;9:699–705.
   PubMed Web of Science ®Google Scholar
• Boehm JC, Davies TG, Woolford -AJ-A, et al., inventors; GlaxoSmithKline Intellectual Property Development Limited, UK; Astex Therapeutics Limited. assignee. Preparation of sulfonylaminophenylpropanoic acid derivatives as Nrf2 regulators. WO2015092713A1. 2015.
   Google Scholar
• Davies TG, Wixted WE, Coyle JE, et al. Monoacidic inhibitors of the kelch-like ECH-associated protein 1: nuclear factor erythroid 2-related factor 2 (KEAP1: NRF2)protein-protein interaction with high cell potency identified by fragment-based discovery. J Med Chem. 2016;59:3991–4006.
   PubMed Web of Science ®Google Scholar
• Satoh M, Saburi H, Tanaka T, et al. Multiple binding modes of a small molecule to human Keap1 revealed by X‐ray crystallography and molecular dynamics simulation. FEBS Open Bio. 2015;5:557–570.
   PubMed Web of Science ®Google Scholar
• Xu LL, Zhu JF, Xu XL, et al. Discovery and modification of in vivo active Nrf2 activators with 1,2,4-oxadiazole core: hits identification and structure-activity relationship Study. J Med Chem. 2015;58:5419–5436.
   PubMed Web of Science ®Google Scholar
• Xu LL, Zhang X, Jiang ZY, et al. Molecular similarity guided optimization of novel Nrf2 activators with 1,2,4-oxadiazole core. Bioorg Med Chem. 2016;24:3540–3547.
   PubMed Web of Science ®Google Scholar
• Bertrand HC, Schaap M, Baird L, et al. Design, synthesis, and evaluation of triazole derivatives that induce Nrf2 dependent gene products and inhibit the keap1-Nrf2 protein-protein interaction. J Med Chem. 2015;58:7186–7194.
   PubMed Web of Science ®Google Scholar
• Kazantsev AG, Thompson LM, Abagyan R, et al., inventors; The General Hospital Corporation, USA; University of California. assignee. Screening methods for identifying small molecule activators of NRF2 pathway and therapeutic uses thereof for treating neurodegenerative diseases. WO2014197818A2. 2014.
   Google Scholar
• Heinäniemi M, Levonen A-L. Role of the Keap1–Nrf2 pathway in cancer. Redox Cancer. 2014;122:281.
   Web of Science ®Google Scholar
• Bollong MJ, Yun H, Sherwood L, et al. A small molecule inhibits deregulated NRF2 transcriptional activity in cancer. ACS Chem Biol. 2015;10:2193–2198.
   PubMed Web of Science ®Google Scholar
• Olayanju A, Copple IM, Bryan HK, et al. Brusatol provokes a rapid and transient inhibition of Nrf2 signaling and sensitizes mammalian cells to chemical toxicity—implications for therapeutic targeting of Nrf2. Free Radic Biol Med. 2015;78:202–212.
   PubMed Web of Science ®Google Scholar
• Song JY, Ahn JY, Jung IS, et al., inventors; Korea Institute of Radiological & Medical Sciences, S. Korea. assignee. Preparation of benzo[d]oxazole derivatives useful as anticancer supplement agents. US20150197498A1. 2015.
   Google Scholar
• Biswal SS, Singh A, Rastinehad F, et al., inventors; The Johns Hopkins University, USA; The National Institutes of Health. assignee. Preparation of small molecule Nrf2 inhibitor for cancer therapy. WO2014145642A2. 2014.
   Google Scholar
• Song JY, Ahn JY, Jung IS, et al., inventors; Korea institute of radiological & medical sciences, S. Korea. assignee. Nrf2 inhibitors for chemotherapy and chemoradiotherapy. KR2013079898A. 2013.
   Google Scholar
• Lee S, Lim MJ, Kim MH, et al. An effective strategy for increasing the radiosensitivity of Human lung Cancer cells by blocking Nrf2-dependent antioxidant responses. Free Radic Biol Med. 2012;53:807–816.
   PubMed Web of Science ®Google Scholar
• Nelson MB, Pi J, Andersen ME, inventors; The Hamner Institutes, USA. assignee. Nuclear factor erythroid 2-related factor (Nrf2) inhibitors for treating mycobacterial infections. WO2015009881A1. 2015.
   Google Scholar
• Pi J, Andersen ME, Xue P, et al., inventors; The Hamner Institutes, USA. assignee. Screening methods for identifying inhibitors of nuclear factor erythroid 2-related factor (Nrf2) and uses thereof for treating tumors and viral infections. WO2015009879A1. 2015.
   Google Scholar
• Bruze M, Zimerson E. Dimethyl fumarate. Dermatitis. 2011;22:3–7.
   PubMed Web of Science ®Google Scholar
• Ahn YH, Hwang Y, Liu H, et al. Electrophilic tuning of the chemoprotective natural product sulforaphane. Proc Natl Acad Sci USA. 2010;107:9590–9595.
   PubMed Web of Science ®Google Scholar
• Maher J, Yamamoto M. The rise of antioxidant signaling—the evolution and hormetic actions of Nrf2. Toxicol Appl Pharmacol. 2010;244:4–15.
   PubMed Web of Science ®Google Scholar